{"gene":"TP73","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1999,"finding":"MDM2 binds p73 both in vivo and in vitro but, unlike with p53, does not promote p73 degradation. Instead, MDM2 suppresses p73 transcriptional activity by disrupting the p73-p300/CBP interaction, competing with p73 for binding to the p300/CBP N-terminus. p73 transcriptionally activates MDM2, forming a regulatory loop distinct from the p53-MDM2 loop.","method":"Co-immunoprecipitation (in vivo and in vitro), transient transfection/CAT reporter assays, apoptosis assays in p53-null cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP in vivo and in vitro, multiple orthogonal functional assays, replicated in multiple cell lines","pmids":["10207051"],"is_preprint":false},{"year":1999,"finding":"MDM2 and MDMX bind p73α and p73β and, in contrast to their effect on p53, stabilize p73 protein (increase half-life) and enhance p73-mediated growth suppression and p21 induction.","method":"Co-immunoprecipitation, half-life assays, growth suppression assays","journal":"Current biology : CB","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding shown, half-life measured, single lab with two orthogonal methods","pmids":["10469568"],"is_preprint":false},{"year":2000,"finding":"Tumor-derived p53 mutants (p53His175 and p53Gly281) physically associate with p73α, β, γ, and δ isoforms in vitro and in vivo. The core domain of mutant p53 is sufficient for the association; both the DNA-binding and oligomerization domains of p73 are required. This interaction functionally inhibits p73 transcriptional activity.","method":"Co-immunoprecipitation in breast cancer cell lines, in vitro binding, transactivation reporter assays, domain-mapping mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro and in vivo binding confirmed, domain mapping by mutagenesis, functional transcriptional assays, verified in endogenous tumor cell context","pmids":["10884390"],"is_preprint":false},{"year":2000,"finding":"E2F-1, c-Myc, and E1A oncogenes induce and activate endogenous p73α and p73β proteins in p53-deficient tumor cells, leading to p73-dependent transcription (p21, HDM2 induction) and apoptosis. A dominant-negative p73 inhibitor blocks oncogene-induced apoptosis.","method":"Western blot, reporter assays, apoptosis assays with dominant-negative p73 inhibitor in p53-null cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple oncogenes tested, functional reporter and apoptosis readouts, dominant-negative rescue, single lab","pmids":["11115495"],"is_preprint":false},{"year":2000,"finding":"TCR-activation-induced cell death (TCR-AICD) requires both E2F-1 and p73 in a common pathway. E2F-1-null or p73-null primary T cells fail to undergo TCR-mediated apoptosis; dominant-negative E2F-1 or dominant-negative p73 protects T cells, whereas dominant-negative p53 does not.","method":"Genetic knockout (E2F-1-null, p73-null primary T cells), dominant-negative protein expression, apoptosis assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic null models plus dominant-negative rescue, p53-null control distinguishes pathway, replicated with two independent genetic systems","pmids":["11034214"],"is_preprint":false},{"year":2001,"finding":"p73 transcription is directly induced by p53 and by p73 itself (autoregulation) through a p53-binding site in the p73 promoter; mutant p53(R249S) and transcriptionally inactive p73β292 do not induce p73 expression.","method":"Reporter assays with p73 promoter constructs, site-directed mutagenesis of promoter binding site, RT-PCR","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter plus mutant controls, two orthogonal methods (reporter + endogenous mRNA), single lab","pmids":["11314010"],"is_preprint":false},{"year":2002,"finding":"Combined loss of p63 and p73 (but not either alone) abolishes p53-dependent apoptosis in response to DNA damage in MEFs expressing E1A and in vivo, demonstrating that p63 and p73 are required co-factors for p53-mediated apoptosis.","method":"Mouse embryo fibroblasts deficient for combinations of p53 family members, E1A oncogene system, in vivo apoptosis assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic double/triple knockout mouse models, both in vitro and in vivo validation, rigorous epistasis analysis","pmids":["11932750"],"is_preprint":false},{"year":2002,"finding":"p73 is selectively expressed in Cajal-Retzius (CR) cells of the developing human cortex; in p73-/- mice, Reelin-expressing CR cells are absent at P2 (though early preplate Reelin from calretinin-positive cells remains), indicating p73 is required for CR cell identity/maintenance and cortical hem-derived neocortical development.","method":"Immunocytochemistry in human prenatal telencephalon, in situ hybridization in p73-/- mice, comparative analysis of p73-/- vs. wild-type cortex","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null mouse model with specific cellular phenotype, confirmed by two methods (IHC + ISH), single lab","pmids":["12077194"],"is_preprint":false},{"year":2003,"finding":"p73 is induced by a broad range of chemotherapeutic drugs; blocking p73 function with dominant-negative mutant, siRNA, or homologous recombination causes chemoresistance regardless of p53 status; mutant p53 can inactivate p73 and downregulation of mutant p53 enhances chemosensitivity.","method":"siRNA knockdown, dominant-negative expression, homologous recombination, chemosensitivity assays","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — three independent methods (DN, siRNA, HR) converge on same phenotype, multiple cell lines tested, direct p53-mutant/p73 functional connection established","pmids":["12726865"],"is_preprint":false},{"year":2004,"finding":"Checkpoint kinases Chk1 and Chk2 control p73 induction at the mRNA level after DNA damage, acting through E2F1 stabilization. Interference with Chk1/Chk2 reduces p73 accumulation; augmentation increases it. E2F1 directs p73 expression both with and without DNA damage.","method":"Multiple experimental systems including kinase interference and augmentation, RT-PCR for p73 mRNA, E2F1 reporter assays","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple experimental systems, mRNA and protein level analysis, single lab with orthogonal approaches","pmids":["15601819"],"is_preprint":false},{"year":2004,"finding":"Wwox physically interacts with p73 via its first WW domain; Src kinase phosphorylates Wwox at Tyr33 and enhances its binding to p73. Wwox expression redistributes nuclear p73 to the cytoplasm, suppressing p73 transcriptional activity; cytoplasmic p73 contributes to Wwox pro-apoptotic activity.","method":"Co-immunoprecipitation, in vitro binding assays, subcellular fractionation, reporter assays, domain mapping","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus subcellular localization plus functional reporter assays, domain mapping, single lab","pmids":["15070730"],"is_preprint":false},{"year":2005,"finding":"Itch, a HECT ubiquitin-protein ligase, selectively binds and ubiquitinates p73 (but not p53), targeting p73 for rapid proteasome-dependent degradation. Upon DNA damage, Itch is downregulated, allowing p73 protein levels to rise.","method":"Co-immunoprecipitation, ubiquitination assays, proteasome inhibitor experiments, Itch knockdown, Western blot for p73 stability","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct ubiquitination assay, Co-IP, proteasome inhibitor confirmation, knockdown rescue, specificity confirmed by lack of effect on p53","pmids":["15678106"],"is_preprint":false},{"year":2005,"finding":"TAp73 induces apoptosis via: (i) direct transactivation of Scotin, causing ER stress; (ii) transactivation of PUMA (strong, lethal) and Bax promoters (weak, insufficient alone); and (iii) potential activation of the CD95 death receptor pathway. TAp73 also transactivates the DeltaNp73 promoter, creating a negative feedback.","method":"Promoter transactivation reporter assays, apoptosis assays in cell culture","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter assays for multiple targets, functional apoptosis readouts, single lab","pmids":["15865927"],"is_preprint":false},{"year":2006,"finding":"YAP1 (Yes-associated protein 1) interacts with p73 via the p73 PPPY motif and competes with Itch for the same binding site on p73, thereby preventing Itch-mediated ubiquitination and proteasomal degradation of p73. YAP1 knockdown reduces p73 accumulation and apoptosis after cisplatin treatment.","method":"Co-immunoprecipitation, competition binding assays, ubiquitination assays, siRNA knockdown, cisplatin treatment","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mechanistic competition between YAP1 and Itch for p73 PPPY motif demonstrated biochemically, ubiquitination assays, functional apoptosis rescue, siRNA validation","pmids":["17110958"],"is_preprint":false},{"year":2006,"finding":"p73 (or p53) directly transactivates endogenous p53 expression through binding to a defined p53-binding site in the p53 promoter; siRNA silencing of p73 reduces p53 transcription, and disruption of p53 autoregulation impairs cell cycle checkpoints and p53-mediated apoptosis.","method":"siRNA knockdown, reporter assays with p53 promoter mutants, RT-PCR for endogenous p53 mRNA, inducible interfering RNA","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter binding site mapped by mutagenesis, siRNA validation of endogenous effect, functional cell cycle phenotype, single lab","pmids":["16849542"],"is_preprint":false},{"year":2007,"finding":"SIRT1 physically binds p73 and suppresses p73-dependent transcriptional activity; SIRT1 deacetylates p73 both in vivo and in vitro, partially inhibiting p73-induced apoptosis.","method":"Co-immunoprecipitation, deacetylation assays in vivo and in vitro, reporter assays, apoptosis assays","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro deacetylation assay plus in vivo confirmation, Co-IP, functional transcription and apoptosis readouts, single lab","pmids":["16998810"],"is_preprint":false},{"year":2007,"finding":"Nutlin-3 disrupts endogenous TAp73α-HDM2 binding in p53-null cells, leading to increased p73 transcriptional activity (Noxa, PUMA, p21 upregulation), prolonged p73 half-life, and enhanced apoptosis; p73 siRNA rescues Nutlin-3-treated cells, confirming p73 dependence.","method":"Co-immunoprecipitation, siRNA knockdown, RT-PCR for target genes, apoptosis assays, p73 half-life measurement","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endogenous Co-IP, siRNA rescue, multiple target gene validation, half-life assay, single lab","pmids":["17700533"],"is_preprint":false},{"year":2007,"finding":"Hck (Src-family kinase) interacts with p73 via its SH3 domain and phosphorylates p73 at Tyr28 (distinct from c-Abl which phosphorylates Tyr99). Hck co-expression stabilizes p73 in the cytoplasm (kinase-dependent) and represses p73 transcriptional activity and p73-mediated apoptosis through SH3-domain-dependent mechanisms.","method":"Co-immunoprecipitation, in vitro binding, site-directed mutagenesis of phosphorylation sites, subcellular fractionation, reporter assays, RT-PCR, apoptosis assays","journal":"BMC molecular biology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — site-directed mutagenesis identifies phosphorylation site, multiple functional readouts, both kinase-dependent and domain-dependent mechanisms, single lab","pmids":["17535448"],"is_preprint":false},{"year":2008,"finding":"p73 is cleaved by caspase-3 and caspase-8 during apoptosis induced by DNA-damaging drugs and TRAIL. TAp73 and caspase-cleavage products localize to mitochondria; recombinant p73 directly induces cytochrome c release from isolated mitochondria. A transcription-deficient TAp73 mutant enhances TRAIL-induced apoptosis, demonstrating transcription-independent pro-apoptotic function.","method":"In vitro caspase cleavage assays, subcellular fractionation, mitochondria isolation with cytochrome c release assay, siRNA knockdown, flow cytometry","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro reconstitution (cytochrome c release), fractionation, caspase cleavage assay, transcription-dead mutant, single lab","pmids":["18362891"],"is_preprint":false},{"year":2009,"finding":"DNA damage-induced p73 activation and subsequent Noxa expression require NF-κB (p65); in p65-null MEFs, genotoxin treatment cannot induce p73 activity or Noxa mRNA expression, and cytochrome c release is compromised.","method":"p65-null MEFs, microarray gene profiling, RT-PCR, cytochrome c release assays","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null MEFs, microarray plus RT-PCR validation, functional apoptosis readout, single lab","pmids":["20195489"],"is_preprint":false},{"year":2011,"finding":"p73 selectively activates DNA damage repair in esophageal cells exposed to bile acids in acidic conditions via c-Abl kinase-dependent activation; p73 transcriptionally regulates base excision repair glycosylases SMUG1 and MUTYH. p73 deficiency in mice recapitulating bile acid exposure results in increased DNA damage.","method":"Human DNA repair PCR array, chromatin immunoprecipitation, reporter assays, c-Abl kinase inhibition, organotypic/traditional cell culture, surgical mouse model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct transcriptional regulation, in vivo mouse model confirms DNA damage phenotype, multiple orthogonal methods, single lab","pmids":["21891782"],"is_preprint":false},{"year":2012,"finding":"Crystal structures of the p73 DNA-binding domain (DBD) tetramer bound to response elements with different spacer lengths reveal that the compact tetramer interface is determined by half-site spacing; a 2-bp spacer unwinds DNA and reduces the tetramerization interface, while a 4-bp spacer prevents tetramerization. Functionally, p73 is more sensitive to spacer length than p53: a 1-bp spacer reduces p73 transactivation by 90%.","method":"X-ray crystallography, transactivation reporter assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures with multiple spacer lengths, directly correlated with functional transactivation data, multiple structures in one study","pmids":["22474346"],"is_preprint":false},{"year":2013,"finding":"TAp73 activates serine biosynthesis in cancer cells not by directly regulating serine metabolic enzymes but by transcriptionally controlling glutaminase-2 (GLS2), a key glutaminolysis enzyme. p73-driven GLS2 expression converts glutamine to glutamate, which drives serine biosynthesis and GSH synthesis. TAp73 depletion abolishes cancer cell proliferation under serine/glycine deprivation.","method":"Metabolic profiling, siRNA knockdown, reporter assays, cell proliferation assays under nutrient deprivation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — metabolic profiling plus functional knockdown, indirect mechanism (via GLS2) established by reporter assays, single lab","pmids":["24186203"],"is_preprint":false},{"year":2013,"finding":"TRIM32 (E3 ubiquitin ligase) is a direct transcriptional target of TAp73 in neural progenitor cells; TRIM32 in turn physically interacts with TAp73 and promotes its ubiquitination and degradation, establishing a negative feedback loop. ΔNp73 represses TRIM32 expression.","method":"ChIP, reporter assays, Co-immunoprecipitation, ubiquitination assays, Western blot","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct promoter binding, ubiquitination assay confirms degradation mechanism, Co-IP confirms physical interaction, single lab","pmids":["23828567"],"is_preprint":false},{"year":2014,"finding":"AMPK phosphorylates p73 on Ser426 in vitro and in vivo. AMPK activation prolongs p73 half-life, increases nuclear p73, and reduces Itch-mediated ubiquitination of p73. Chronic AMPK activation leads to p73-dependent apoptosis only in p53-expressing cells; p73 is required for p53 stabilization under AMPK activation but not under DNA damage.","method":"In vitro kinase assay, in vivo phosphorylation assay, half-life measurement, ubiquitination assays, p73 knockdown, co-immunoprecipitation","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay identifies phosphorylation site, in vivo confirmation, functional consequences measured by multiple methods, single rigorous study","pmids":["24874608"],"is_preprint":false},{"year":2014,"finding":"MDM2 differentially regulates mutant p53 interactions with p63 and p73: MDM2 inhibits p63 binding to p53R175H (conformational mutant) but enhances the weaker p53R273H/p73 interaction. MDM2 can relieve p63 inhibition by p53R175H but forms a trimeric complex with p73 and p53R273H/R175H to enhance p73 inhibition.","method":"Co-immunoprecipitation, reporter assays, domain mapping","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional reporter assays, differential effects mapped across mutants, single lab","pmids":["25417702"],"is_preprint":false},{"year":2015,"finding":"NAMPT inhibition stabilizes p73 independently of p53 through increased acetylation and decreased ubiquitination, leading to enhanced autophagy and cancer cell death; these effects are reversed by NMN (the NAMPT enzymatic product), establishing a NAMPT-p73 nexus in cancer cell viability.","method":"NAMPT pharmacological inhibition and siRNA knockdown, p73 overexpression/knockdown, ubiquitination assays, Western blot, cell viability assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic inhibition converge, rescue with enzymatic product, ubiquitination assays, single lab","pmids":["26586573"],"is_preprint":false},{"year":2015,"finding":"p73 is required for ependymal cell maturation and planar cell polarity establishment in the developing SVZ; p73-deficient ependymal cells have impaired ciliogenesis and fail to organize into pinwheels, disrupting SVZ niche architecture and neurogenesis.","method":"Genetic knockout mouse model (p73-null), immunofluorescence, electron microscopy, neurogenesis assays","journal":"Developmental neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null model with defined cellular phenotype (ciliogenesis, pinwheel organization), multiple morphological methods, single lab","pmids":["26482843"],"is_preprint":false},{"year":2016,"finding":"p73 is expressed in multiciliated cells (MCCs) and is required for MCC differentiation; p73 directly regulates Foxj1 (a master transcriptional regulator of multiciliogenesis) and >100 cilia-associated target genes. Loss of p73 causes defects in ciliogenesis explaining hydrocephalus, hippocampal dysgenesis, sterility, and chronic inflammation in p73-null mice.","method":"ChIP-seq (p73 and p63) in murine tracheal cells, genetic knockout mice, reporter assays, immunofluorescence","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP-seq identifies direct target genes, genetic null model confirms phenotype, validated across multiple target genes with orthogonal methods","pmids":["26947080"],"is_preprint":false},{"year":2016,"finding":"TAp73 directly activates POSTN (periostin) transcription in glioblastoma cells, conferring an invasive phenotype. POSTN overexpression rescues the reduced invasiveness caused by p73 knockdown, placing POSTN downstream of TAp73 in a pro-invasion pathway.","method":"ChIP, reporter assays, siRNA knockdown, invasion assays, rescue experiments with POSTN overexpression","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct promoter binding, siRNA knockdown with functional readout, rescue experiment validates pathway, single lab","pmids":["26930720"],"is_preprint":false},{"year":2018,"finding":"Δ133p53 forms a complex with p73 upon γ-irradiation; co-expression of Δ133p53 and p73 synergistically promotes DNA DSB repair (HR, NHEJ, SSA) by jointly binding to both a Δ133p53-responsive element and a p73-RE in the promoters of RAD51, LIG4, and RAD52. Loss of p73 increases DNA damage accumulation and leads to cell cycle arrest and senescence.","method":"Co-immunoprecipitation, ChIP, reporter assays, γ-irradiation, HR/NHEJ/SSA repair assays, siRNA knockdown","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and co-IP confirm complex formation at target promoters, multiple repair pathway assays, functional phenotype with siRNA, single lab","pmids":["29511339"],"is_preprint":false},{"year":2018,"finding":"JNK-mediated phosphorylation of Thr81 in the proline-rich domain of p53 enables wild-type p53 (as well as mutant p53) to form a complex with p73. Wild-type p53/p73 dimerization facilitates expression of apoptotic target genes (PUMA, BAX) and promotes apoptosis; mutant p53/p73 complex suppresses apoptosis.","method":"Co-immunoprecipitation, phosphorylation assays, structural modeling, reporter assays, apoptosis assays, site-directed mutagenesis of Thr81","journal":"Science signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with phosphomimetic and phospho-dead mutants, functional apoptosis readouts, structural prediction, single lab","pmids":["29615516"],"is_preprint":false},{"year":2018,"finding":"TAp73 is an essential regulator of ependymal planar cell polarity (PCP) by modulating actin and microtubule cytoskeleton dynamics. TAp73 regulates translational PCP and actin dynamics through modulation of non-muscle myosin-II activity and controls asymmetric localization of PCP-core signaling modules and polarized microtubule dynamics for rotational PCP.","method":"TAp73-specific knockout mice, immunofluorescence for PCP proteins and cytoskeletal markers, analysis of myosin-II activity","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific genetic null model, multiple cytoskeletal readouts, mechanistic link to non-muscle myosin-II, single lab","pmids":["30518789"],"is_preprint":false}],"current_model":"TP73 encodes a p53-family transcription factor that is activated by DNA damage (via the Chk1/Chk2–E2F1 axis and c-Abl-dependent mechanisms), stabilized by YAP1 and AMPK-mediated phosphorylation (Ser426) competing with Itch-mediated ubiquitination and degradation, and that directly transactivates pro-apoptotic targets (PUMA, Bax, CD95, Noxa) and DNA repair genes (SMUG1, MUTYH, RAD51, LIG4); it is also a master transcriptional regulator of multiciliogenesis (via Foxj1 and cilia-associated genes), ependymal planar cell polarity (via non-muscle myosin-II and cytoskeletal dynamics), and Cajal-Retzius cell identity in the developing cortex, while its activity is inhibited by dominant-negative ΔNp73 isoforms, mutant p53 (gain-of-function binding to p73's DNA-binding domain), MDM2 (which blocks p73–p300/CBP interaction), SIRT1 (deacetylation), and WWOX (cytoplasmic sequestration)."},"narrative":{"mechanistic_narrative":"TP73 encodes a p53-family transcription factor that operates as a stress-activated transcriptional hub coupling genotoxic and oncogenic signals to apoptosis, DNA repair, and developmental cell-fate programs [PMID:11034214, PMID:12726865, PMID:26947080]. Following DNA damage, p73 is induced at the mRNA level through a Chk1/Chk2-E2F1 axis [PMID:15601819], and p73-dependent apoptosis is a shared output with E2F1 (as in TCR-activation-induced T-cell death) that operates independently of p53 [PMID:11034214]; p63 and p73 together are required co-factors for p53-mediated apoptosis after DNA damage [PMID:11932750]. Once stabilized, TAp73 directly transactivates pro-apoptotic targets including PUMA, Bax, Scotin, and Noxa — the latter requiring NF-κB (p65) [PMID:15865927, PMID:20195489] — and also acts transcription-independently at mitochondria, where caspase-cleaved p73 drives cytochrome c release [PMID:18362891]. p73 additionally directs DNA repair, transcribing the base-excision-repair glycosylases SMUG1 and MUTYH via c-Abl-dependent activation [PMID:21891782] and, in complex with Δ133p53, the double-strand-break repair genes RAD51, LIG4, and RAD52 [PMID:29511339]. p73 abundance is set by a balance of ubiquitin-dependent turnover and stabilizing modifications: the HECT ligase Itch selectively ubiquitinates p73 for proteasomal degradation and is downregulated upon DNA damage [PMID:15678106], while YAP1 competes with Itch for the p73 PPPY motif to protect it [PMID:17110958] and AMPK phosphorylation at Ser426 prolongs its half-life by reducing Itch-mediated ubiquitination [PMID:24874608]. Its transcriptional activity is further restrained by MDM2, which disrupts the p73-p300/CBP interaction [PMID:10207051], by tumor-derived mutant p53 that binds the p73 DNA-binding/oligomerization domains [PMID:10884390], by SIRT1-mediated deacetylation [PMID:16998810], and by WWOX-driven cytoplasmic sequestration [PMID:15070730]. Beyond tumor suppression, p73 is a master regulator of multiciliogenesis, directly controlling Foxj1 and >100 cilia genes [PMID:26947080], and is required for ependymal planar cell polarity through non-muscle myosin-II and cytoskeletal dynamics [PMID:30518789] and for Cajal-Retzius cell identity in the developing cortex [PMID:12077194]. Crystallographic analysis shows the p73 DNA-binding domain tetramerizes on response elements in a manner acutely sensitive to half-site spacing [PMID:22474346].","teleology":[{"year":1999,"claim":"Established that p73, despite binding MDM2, is regulated differently from p53 — MDM2 inhibits p73 transcription by displacing p300/CBP rather than degrading it, defining a distinct regulatory loop.","evidence":"Reciprocal Co-IP in vivo/in vitro plus CAT reporter and apoptosis assays in p53-null cells","pmids":["10207051","10469568"],"confidence":"High","gaps":["Conflicting reports on whether MDM2/MDMX stabilize versus suppress p73 activity","Physiological conditions favoring each outcome not defined"]},{"year":2000,"claim":"Connected p73 to oncogene- and damage-driven apoptosis independent of p53, showing E2F1/c-Myc/E1A activate endogenous p73 and that p73 is required for TCR-induced T-cell death.","evidence":"Dominant-negative inhibition, genetic E2F1-null and p73-null primary T cells, apoptosis assays","pmids":["11115495","11034214","10884390"],"confidence":"High","gaps":["Direct transcriptional targets driving apoptosis not yet enumerated","Mechanism by which mutant p53 inhibits p73 mapped only to domains, not at structural resolution"]},{"year":2002,"claim":"Showed p63 and p73 are jointly required for p53-dependent apoptosis and that p73 marks Cajal-Retzius cells, establishing both a tumor-suppressor cofactor role and a developmental function.","evidence":"Combinatorial p53-family knockout MEFs/in vivo; immunocytochemistry and ISH in p73-/- cortex","pmids":["11932750","12077194"],"confidence":"High","gaps":["Molecular basis of p63/p73 cooperativity with p53 not resolved","Cajal-Retzius transcriptional targets of p73 unidentified"]},{"year":2003,"claim":"Defined p73 as a determinant of chemosensitivity across p53 backgrounds, with mutant p53 acting as an inhibitor that can be relieved to restore drug response.","evidence":"Convergent siRNA, dominant-negative, and homologous-recombination loss-of-function chemosensitivity assays","pmids":["12726865"],"confidence":"High","gaps":["Which p73 target genes mediate chemosensitivity not specified","Generalizability across tumor types not established"]},{"year":2004,"claim":"Identified the upstream signaling that induces p73 after DNA damage, placing Chk1/Chk2 and E2F1 stabilization upstream of p73 mRNA accumulation.","evidence":"Kinase interference/augmentation, RT-PCR, E2F1 reporter assays","pmids":["15601819"],"confidence":"Medium","gaps":["Direct E2F1 occupancy of the p73 promoter not shown here","Relative contribution of Chk1 versus Chk2 unresolved"]},{"year":2004,"claim":"Revealed cytoplasmic sequestration as a control point: WWOX binds p73 and relocalizes it to the cytoplasm, with Src-mediated phosphorylation tuning the interaction.","evidence":"Co-IP, in vitro binding, subcellular fractionation, domain mapping, reporter assays","pmids":["15070730"],"confidence":"Medium","gaps":["Single-lab finding without reciprocal validation in other systems","Physiological signals controlling WWOX-p73 partitioning unclear"]},{"year":2005,"claim":"Defined the dominant proteostatic control of p73 — Itch-mediated, p53-sparing ubiquitination and degradation that is relieved by DNA damage.","evidence":"Ubiquitination assays, Co-IP, proteasome inhibition, Itch knockdown","pmids":["15678106","15865927"],"confidence":"High","gaps":["Signal that downregulates Itch after damage not defined","Isoform selectivity of Itch toward TA versus ΔNp73 not addressed"]},{"year":2006,"claim":"Mapped the molecular logic of p73 stabilization: YAP1 competes with Itch at the p73 PPPY motif to protect it from degradation, gating cisplatin-induced apoptosis.","evidence":"Competition binding and ubiquitination assays, siRNA, cisplatin treatment","pmids":["17110958","16849542"],"confidence":"High","gaps":["Upstream regulators of YAP1-p73 binding under damage not defined","How p73-driven p53 autoregulation integrates with this axis unclear"]},{"year":2007,"claim":"Expanded the inhibitory and pharmacological control of p73 — SIRT1 deacetylation and Hck-mediated cytoplasmic retention repress activity, while Nutlin-3 frees p73 from HDM2 to drive apoptosis in p53-null cells.","evidence":"Co-IP, in vitro/in vivo deacetylation, site-directed mutagenesis, endogenous Co-IP, siRNA rescue, target-gene RT-PCR","pmids":["16998810","17535448","17700533"],"confidence":"Medium","gaps":["Each mechanism shown by a single lab without cross-validation","In vivo relevance of Hck and SIRT1 control of p73 not established"]},{"year":2008,"claim":"Demonstrated a transcription-independent, mitochondrial arm of p73 apoptosis, with caspase cleavage products directly triggering cytochrome c release.","evidence":"In vitro caspase cleavage, mitochondrial fractionation and cytochrome c release, transcription-dead mutant, flow cytometry","pmids":["18362891"],"confidence":"Medium","gaps":["Structural basis of p73 action at mitochondria unknown","Relative contribution of transcriptional versus mitochondrial arms in vivo unresolved"]},{"year":2009,"claim":"Placed NF-κB (p65) as a required cofactor for damage-induced p73 activity and Noxa induction, linking inflammatory signaling to p73-driven apoptosis.","evidence":"p65-null MEFs, microarray and RT-PCR, cytochrome c release","pmids":["20195489"],"confidence":"Medium","gaps":["Direct physical p65-p73 interaction not demonstrated here","Mechanism of p65 requirement (cofactor vs upstream) unclear"]},{"year":2011,"claim":"Established p73 as a direct transcriptional activator of DNA repair, controlling base-excision-repair glycosylases SMUG1 and MUTYH via c-Abl in genotoxin-exposed epithelium.","evidence":"ChIP, DNA-repair PCR array, reporter assays, c-Abl inhibition, surgical mouse model","pmids":["21891782"],"confidence":"Medium","gaps":["Breadth of p73-regulated repair genes beyond BER not defined here","Single-lab finding in a specialized esophageal context"]},{"year":2012,"claim":"Provided the structural basis for p73 DNA recognition, showing tetramerization on response elements is acutely sensitive to half-site spacing — more so than p53.","evidence":"X-ray crystallography of DBD tetramers with varied spacers, transactivation assays","pmids":["22474346"],"confidence":"High","gaps":["Full-length p73 structure and isoform differences not captured","How cofactors alter response-element selectivity unknown"]},{"year":2013,"claim":"Extended p73's reach to metabolism and developmental feedback — driving serine biosynthesis via GLS2 and forming a TRIM32 negative-feedback loop in neural progenitors.","evidence":"Metabolic profiling, siRNA, ChIP, Co-IP, ubiquitination assays, proliferation under nutrient deprivation","pmids":["24186203","23828567"],"confidence":"Medium","gaps":["Direct versus indirect metabolic targets only partially separated","Physiological context of TRIM32 feedback beyond neural progenitors unknown"]},{"year":2014,"claim":"Identified AMPK Ser426 phosphorylation as a stabilizing signal that opposes Itch and integrates energy stress with p73-dependent apoptosis, and detailed MDM2's differential modulation of mutant-p53/p73 complexes.","evidence":"In vitro/in vivo kinase and ubiquitination assays, half-life measurement, p73 knockdown; Co-IP and reporter assays across p53 mutants","pmids":["24874608","25417702"],"confidence":"High","gaps":["How AMPK and DNA-damage inputs are prioritized at p73 unclear","Trimeric MDM2/mutant-p53/p73 complex stoichiometry not resolved"]},{"year":2015,"claim":"Refined p73 proteostatic control through metabolism, showing NAMPT inhibition stabilizes p73 via increased acetylation and decreased ubiquitination to drive autophagy and death; ependymal maturation and PCP also depend on p73.","evidence":"NAMPT pharmacological/genetic inhibition with NMN rescue, ubiquitination assays; p73-null mouse SVZ imaging and EM","pmids":["26586573","26482843"],"confidence":"Medium","gaps":["Enzyme(s) mediating NAMPT-dependent p73 acetylation not identified","Direct p73 targets driving ependymal ciliogenesis not enumerated here"]},{"year":2016,"claim":"Defined p73 as the master transcriptional driver of multiciliogenesis through direct control of Foxj1 and cilia genes, and as a pro-invasion factor via POSTN in glioblastoma.","evidence":"ChIP-seq in tracheal cells, knockout mice, reporter assays; ChIP, siRNA, invasion and rescue assays","pmids":["26947080","26930720"],"confidence":"High","gaps":["Isoform (TA vs ΔN) responsible for cilia program not fully dissected","Cofactors directing p73 to cilia versus apoptotic promoters unknown"]},{"year":2018,"claim":"Established cooperative complexes that diversify p73 output — Δ133p53/p73 promoting DSB repair gene expression, and JNK-driven p53-Thr81 phosphorylation enabling wild-type or mutant p53/p73 dimers with opposite apoptotic outcomes; TAp73 controls ependymal PCP via myosin-II and cytoskeletal dynamics.","evidence":"Co-IP, ChIP, HR/NHEJ/SSA repair assays; phosphomutant Co-IP and apoptosis assays; isoform-specific knockout mice with cytoskeletal imaging","pmids":["29511339","29615516","30518789"],"confidence":"Medium","gaps":["Structural basis of p53-isoform/p73 heterocomplexes not resolved","How the same complexes switch between repair and apoptosis outputs unclear"]},{"year":null,"claim":"How the many competing inputs (Itch/YAP1/AMPK turnover, SIRT1/MDM2/WWOX inhibition, p53-isoform complexes) are integrated to select between p73's apoptotic, DNA-repair, metabolic, and ciliogenic programs in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking post-translational state to target-gene program choice","Isoform-resolved (TAp73 vs ΔNp73) genome-wide occupancy across contexts incomplete","In vivo hierarchy of stabilizing versus degrading inputs undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[12,20,28,29,30]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[21,30]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[10,24]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10,17]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[18]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,12,18]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[12,28]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[20,30]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,27,28,32]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[26]}],"complexes":[],"partners":["MDM2","TP53","YAP1","ITCH","WWOX","SIRT1","TRIM32","TP63"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15350","full_name":"Tumor protein p73","aliases":["p53-like transcription factor","p53-related protein"],"length_aa":636,"mass_kda":69.6,"function":"Participates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein. Is an activator of FOXJ1 expression (By similarity). It is an essential factor for the positive regulation of lung ciliated cell differentiation (PubMed:34077761)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/O15350/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TP73","classification":"Not Classified","n_dependent_lines":18,"n_total_lines":1208,"dependency_fraction":0.014900662251655629},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TP73","total_profiled":1310},"omim":[{"mim_id":"619466","title":"CILIARY DYSKINESIA, PRIMARY, 47, AND LISSENCEPHALY; CILD47","url":"https://www.omim.org/entry/619466"},{"mim_id":"617245","title":"HECT, C2, AND WW DOMAINS-CONTAINING E3 UBIQUITIN-PROTEIN LIGASE 2; HECW2","url":"https://www.omim.org/entry/617245"},{"mim_id":"616761","title":"SUSHI DOMAIN-CONTAINING PROTEIN 6; SUSD6","url":"https://www.omim.org/entry/616761"},{"mim_id":"613126","title":"PROLINE/SERINE-RICH COILED-COIL PROTEIN 1; PSRC1","url":"https://www.omim.org/entry/613126"},{"mim_id":"612814","title":"SPERMATOGENESIS-ASSOCIATED PROTEIN 18; SPATA18","url":"https://www.omim.org/entry/612814"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Golgi apparatus","reliability":"Additional"},{"location":"Vesicles","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"},{"location":"Cell Junctions","reliability":"Additional"},{"location":"Centrosome","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":6.0},{"tissue":"fallopian tube","ntpm":6.3},{"tissue":"skin 1","ntpm":6.2}],"url":"https://www.proteinatlas.org/search/TP73"},"hgnc":{"alias_symbol":["P73"],"prev_symbol":[]},"alphafold":{"accession":"O15350","domains":[{"cath_id":"2.60.40.720","chopping":"129-310","consensus_level":"high","plddt":94.3897,"start":129,"end":310},{"cath_id":"1.10.150.50","chopping":"492-553","consensus_level":"high","plddt":85.8532,"start":492,"end":553}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15350","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15350-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15350-F1-predicted_aligned_error_v6.png","plddt_mean":65.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TP73","jax_strain_url":"https://www.jax.org/strain/search?query=TP73"},"sequence":{"accession":"O15350","fasta_url":"https://rest.uniprot.org/uniprotkb/O15350.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15350/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15350"}},"corpus_meta":[{"pmid":"11932750","id":"PMC_11932750","title":"p63 and p73 are required for p53-dependent apoptosis in response to DNA damage.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11932750","citation_count":700,"is_preprint":false},{"pmid":"10769197","id":"PMC_10769197","title":"The p53/p63/p73 family of transcription factors: overlapping and distinct functions.","date":"2000","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/10769197","citation_count":445,"is_preprint":false},{"pmid":"11818141","id":"PMC_11818141","title":"On the shoulders of giants: p63, p73 and the rise of p53.","date":"2002","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/11818141","citation_count":430,"is_preprint":false},{"pmid":"11252895","id":"PMC_11252895","title":"P63 and P73: P53 mimics, menaces and more.","date":"2000","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11252895","citation_count":419,"is_preprint":false},{"pmid":"15280445","id":"PMC_15280445","title":"p63 and p73: roles in development and tumor formation.","date":"2004","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/15280445","citation_count":392,"is_preprint":false},{"pmid":"12726865","id":"PMC_12726865","title":"Chemosensitivity linked to p73 function.","date":"2003","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12726865","citation_count":367,"is_preprint":false},{"pmid":"10207051","id":"PMC_10207051","title":"MDM2 suppresses p73 function without promoting p73 degradation.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10207051","citation_count":298,"is_preprint":false},{"pmid":"11034214","id":"PMC_11034214","title":"A common E2F-1 and p73 pathway mediates cell death induced by TCR activation.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11034214","citation_count":281,"is_preprint":false},{"pmid":"15678106","id":"PMC_15678106","title":"The ubiquitin-protein ligase Itch regulates p73 stability.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15678106","citation_count":279,"is_preprint":false},{"pmid":"14659698","id":"PMC_14659698","title":"Functional regulation of p73 and p63: development and cancer.","date":"2003","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/14659698","citation_count":247,"is_preprint":false},{"pmid":"17334395","id":"PMC_17334395","title":"p63 and p73 in human cancer: defining the network.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17334395","citation_count":213,"is_preprint":false},{"pmid":"10884390","id":"PMC_10884390","title":"Physical and functional interaction between p53 mutants and different isoforms of p73.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10884390","citation_count":211,"is_preprint":false},{"pmid":"15070730","id":"PMC_15070730","title":"Functional association between Wwox tumor suppressor protein and p73, a p53 homolog.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15070730","citation_count":209,"is_preprint":false},{"pmid":"15601819","id":"PMC_15601819","title":"p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2.","date":"2004","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15601819","citation_count":194,"is_preprint":false},{"pmid":"17110958","id":"PMC_17110958","title":"The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73.","date":"2006","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/17110958","citation_count":176,"is_preprint":false},{"pmid":"17700533","id":"PMC_17700533","title":"HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17700533","citation_count":158,"is_preprint":false},{"pmid":"12077194","id":"PMC_12077194","title":"Expression of p73 and Reelin in the developing human cortex.","date":"2002","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12077194","citation_count":147,"is_preprint":false},{"pmid":"11859406","id":"PMC_11859406","title":"Role of p73 in malignancy: tumor suppressor or oncogene?","date":"2002","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/11859406","citation_count":142,"is_preprint":false},{"pmid":"15865927","id":"PMC_15865927","title":"p73 induces apoptosis by different mechanisms.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15865927","citation_count":128,"is_preprint":false},{"pmid":"21779517","id":"PMC_21779517","title":"p73 in Cancer.","date":"2011","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21779517","citation_count":127,"is_preprint":false},{"pmid":"10873608","id":"PMC_10873608","title":"p63 and p73 transactivate differentiation gene promoters in human keratinocytes.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10873608","citation_count":124,"is_preprint":false},{"pmid":"11115495","id":"PMC_11115495","title":"Oncogenes induce and activate endogenous p73 protein.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11115495","citation_count":124,"is_preprint":false},{"pmid":"26947080","id":"PMC_26947080","title":"p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26947080","citation_count":123,"is_preprint":false},{"pmid":"17287142","id":"PMC_17287142","title":"One, two, three--p53, p63, p73 and chemosensitivity.","date":"2007","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/17287142","citation_count":120,"is_preprint":false},{"pmid":"10469568","id":"PMC_10469568","title":"MDM2 and MDMX bind and stabilize the p53-related protein p73.","date":"1999","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/10469568","citation_count":119,"is_preprint":false},{"pmid":"24488880","id":"PMC_24488880","title":"How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors.","date":"2014","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24488880","citation_count":116,"is_preprint":false},{"pmid":"19816568","id":"PMC_19816568","title":"p63 and p73 transcriptionally regulate genes involved in DNA repair.","date":"2009","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19816568","citation_count":115,"is_preprint":false},{"pmid":"16271066","id":"PMC_16271066","title":"p73, a sophisticated p53 family member in the cancer world.","date":"2005","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/16271066","citation_count":114,"is_preprint":false},{"pmid":"18406616","id":"PMC_18406616","title":"The impact of p53 and p73 on aneuploidy and cancer.","date":"2008","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18406616","citation_count":112,"is_preprint":false},{"pmid":"16998810","id":"PMC_16998810","title":"SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity.","date":"2007","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16998810","citation_count":112,"is_preprint":false},{"pmid":"24186203","id":"PMC_24186203","title":"p73 regulates serine biosynthesis in cancer.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24186203","citation_count":110,"is_preprint":false},{"pmid":"10637429","id":"PMC_10637429","title":"Structure, function and regulation of p63 and p73.","date":"1999","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/10637429","citation_count":108,"is_preprint":false},{"pmid":"11193045","id":"PMC_11193045","title":"Evolution of functions within the p53/p63/p73 family.","date":"2000","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11193045","citation_count":105,"is_preprint":false},{"pmid":"11825686","id":"PMC_11825686","title":"p53, p63 and p73--solos, alliances and feuds among family members.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11825686","citation_count":104,"is_preprint":false},{"pmid":"25417702","id":"PMC_25417702","title":"Functional interplay between MDM2, p63/p73 and mutant p53.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25417702","citation_count":96,"is_preprint":false},{"pmid":"16849542","id":"PMC_16849542","title":"p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16849542","citation_count":91,"is_preprint":false},{"pmid":"11223031","id":"PMC_11223031","title":"From p63 to p53 across p73.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11223031","citation_count":84,"is_preprint":false},{"pmid":"14737098","id":"PMC_14737098","title":"p53 protein variants: structural and functional similarities with p63 and p73 isoforms.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14737098","citation_count":83,"is_preprint":false},{"pmid":"11314010","id":"PMC_11314010","title":"p73 is transcriptionally regulated by DNA damage, p53, and p73.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11314010","citation_count":83,"is_preprint":false},{"pmid":"10732753","id":"PMC_10732753","title":"Mutation analysis of P73 and TP53 in Merkel cell carcinoma.","date":"2000","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10732753","citation_count":79,"is_preprint":false},{"pmid":"9796703","id":"PMC_9796703","title":"Loss of imprinting and allele switching of p73 in renal cell carcinoma.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9796703","citation_count":70,"is_preprint":false},{"pmid":"21380933","id":"PMC_21380933","title":"p73: a multifunctional protein in neurobiology.","date":"2011","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/21380933","citation_count":68,"is_preprint":false},{"pmid":"10383132","id":"PMC_10383132","title":"Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10383132","citation_count":66,"is_preprint":false},{"pmid":"28639399","id":"PMC_28639399","title":"TP73-AS1 promotes breast cancer cell proliferation through miR-200a-mediated TFAM inhibition.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28639399","citation_count":65,"is_preprint":false},{"pmid":"10562283","id":"PMC_10562283","title":"Comparative analysis of p73 and p53 regulation and effector functions.","date":"1999","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10562283","citation_count":65,"is_preprint":false},{"pmid":"17982488","id":"PMC_17982488","title":"Wild-type p53 and p73 negatively regulate expression of proliferation related genes.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17982488","citation_count":62,"is_preprint":false},{"pmid":"15865926","id":"PMC_15865926","title":"Regulation of the p73 protein stability and degradation.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15865926","citation_count":60,"is_preprint":false},{"pmid":"11526499","id":"PMC_11526499","title":"Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11526499","citation_count":60,"is_preprint":false},{"pmid":"22419114","id":"PMC_22419114","title":"Regulation of p73 activity by post-translational modifications.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/22419114","citation_count":58,"is_preprint":false},{"pmid":"11595834","id":"PMC_11595834","title":"p73 in apoptosis.","date":"2001","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/11595834","citation_count":56,"is_preprint":false},{"pmid":"14555234","id":"PMC_14555234","title":"p73 and p63 protein stability: the way to regulate function?","date":"2003","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14555234","citation_count":54,"is_preprint":false},{"pmid":"29733853","id":"PMC_29733853","title":"p73 Alternative Splicing: Exploring a Biological Role for the C-Terminal Isoforms.","date":"2018","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29733853","citation_count":54,"is_preprint":false},{"pmid":"26586573","id":"PMC_26586573","title":"The NAD(+) salvage pathway modulates cancer cell viability via p73.","date":"2015","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26586573","citation_count":54,"is_preprint":false},{"pmid":"29511339","id":"PMC_29511339","title":"p73 coordinates with Δ133p53 to promote DNA double-strand break repair.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29511339","citation_count":54,"is_preprint":false},{"pmid":"18362891","id":"PMC_18362891","title":"P73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18362891","citation_count":51,"is_preprint":false},{"pmid":"25441426","id":"PMC_25441426","title":"Structure and apoptotic function of p73.","date":"2015","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/25441426","citation_count":50,"is_preprint":false},{"pmid":"12944917","id":"PMC_12944917","title":"Differential regulation of p63 and p73 expression.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12944917","citation_count":50,"is_preprint":false},{"pmid":"18348649","id":"PMC_18348649","title":"Contribution of p53, p63, and p73 to the developmental diseases and cancer.","date":"2008","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/18348649","citation_count":49,"is_preprint":false},{"pmid":"18801697","id":"PMC_18801697","title":"Therapeutic prospects for p73 and p63: rising from the shadow of p53.","date":"2008","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/18801697","citation_count":49,"is_preprint":false},{"pmid":"11027640","id":"PMC_11027640","title":"Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11027640","citation_count":48,"is_preprint":false},{"pmid":"25201187","id":"PMC_25201187","title":"Alterations of p63 and p73 in human cancers.","date":"2014","source":"Sub-cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25201187","citation_count":46,"is_preprint":false},{"pmid":"17170001","id":"PMC_17170001","title":"p53 and p73 display common and distinct requirements for sequence specific binding to DNA.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17170001","citation_count":45,"is_preprint":false},{"pmid":"35314772","id":"PMC_35314772","title":"Structural diversity of p63 and p73 isoforms.","date":"2022","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/35314772","citation_count":44,"is_preprint":false},{"pmid":"26482843","id":"PMC_26482843","title":"p73 is required for ependymal cell maturation and neurogenic SVZ cytoarchitecture.","date":"2015","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26482843","citation_count":43,"is_preprint":false},{"pmid":"21891782","id":"PMC_21891782","title":"p73 protein regulates DNA damage repair.","date":"2011","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/21891782","citation_count":42,"is_preprint":false},{"pmid":"15254416","id":"PMC_15254416","title":"p73 and p63: why do we still need them?","date":"2004","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/15254416","citation_count":41,"is_preprint":false},{"pmid":"17626635","id":"PMC_17626635","title":"Overexpressed TP73 induces apoptosis in medulloblastoma.","date":"2007","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17626635","citation_count":41,"is_preprint":false},{"pmid":"22474346","id":"PMC_22474346","title":"Structure of p73 DNA-binding domain tetramer modulates p73 transactivation.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22474346","citation_count":40,"is_preprint":false},{"pmid":"15752257","id":"PMC_15752257","title":"Expression of p63 and p73 in ameloblastomas.","date":"2005","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15752257","citation_count":40,"is_preprint":false},{"pmid":"21903324","id":"PMC_21903324","title":"Targeting p73 in cancer.","date":"2011","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/21903324","citation_count":39,"is_preprint":false},{"pmid":"30420492","id":"PMC_30420492","title":"TP73 G4C14-A4T14 polymorphism and cancer susceptibility: evidence from 36 case-control studies.","date":"2018","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/30420492","citation_count":39,"is_preprint":false},{"pmid":"24874608","id":"PMC_24874608","title":"AMPK couples p73 with p53 in cell fate decision.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/24874608","citation_count":39,"is_preprint":false},{"pmid":"18583938","id":"PMC_18583938","title":"In good times and bad: p73 in cancer.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18583938","citation_count":38,"is_preprint":false},{"pmid":"16541141","id":"PMC_16541141","title":"The role of p73 in hematological malignancies.","date":"2006","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/16541141","citation_count":37,"is_preprint":false},{"pmid":"10221564","id":"PMC_10221564","title":"Mutation and expression analysis of the p73 gene in prostate cancer.","date":"1999","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/10221564","citation_count":37,"is_preprint":false},{"pmid":"31582429","id":"PMC_31582429","title":"Tissue-specific roles of p73 in development and homeostasis.","date":"2019","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/31582429","citation_count":36,"is_preprint":false},{"pmid":"24983500","id":"PMC_24983500","title":"TP63 and TP73 in cancer, an unresolved \"family\" puzzle of complexity, redundancy and hierarchy.","date":"2014","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/24983500","citation_count":36,"is_preprint":false},{"pmid":"22497596","id":"PMC_22497596","title":"Role of p53 family members p73 and p63 in human hematological malignancies.","date":"2012","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/22497596","citation_count":36,"is_preprint":false},{"pmid":"16687923","id":"PMC_16687923","title":"p63 and p73: life and death in squamous cell carcinoma.","date":"2006","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/16687923","citation_count":36,"is_preprint":false},{"pmid":"10962441","id":"PMC_10962441","title":"Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours.","date":"2000","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10962441","citation_count":36,"is_preprint":false},{"pmid":"17428654","id":"PMC_17428654","title":"p73: a chiaroscuro gene in cancer.","date":"2007","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/17428654","citation_count":35,"is_preprint":false},{"pmid":"29615516","id":"PMC_29615516","title":"Mutant and wild-type p53 form complexes with p73 upon phosphorylation by the kinase JNK.","date":"2018","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/29615516","citation_count":35,"is_preprint":false},{"pmid":"15865923","id":"PMC_15865923","title":"p73-induced apoptosis: a question of compartments and cooperation.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15865923","citation_count":34,"is_preprint":false},{"pmid":"26930720","id":"PMC_26930720","title":"p73 promotes glioblastoma cell invasion by directly activating POSTN (periostin) expression.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26930720","citation_count":34,"is_preprint":false},{"pmid":"30518789","id":"PMC_30518789","title":"p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30518789","citation_count":33,"is_preprint":false},{"pmid":"21391908","id":"PMC_21391908","title":"p73 as a pharmaceutical target for cancer therapy.","date":"2011","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/21391908","citation_count":33,"is_preprint":false},{"pmid":"12865464","id":"PMC_12865464","title":"p73 Overexpression and angiogenesis in human colorectal carcinoma.","date":"2003","source":"Japanese journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12865464","citation_count":33,"is_preprint":false},{"pmid":"20195489","id":"PMC_20195489","title":"Activation of p73 and induction of Noxa by DNA damage requires NF-kappa B.","date":"2009","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/20195489","citation_count":33,"is_preprint":false},{"pmid":"15650240","id":"PMC_15650240","title":"Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology.","date":"2004","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15650240","citation_count":32,"is_preprint":false},{"pmid":"23828567","id":"PMC_23828567","title":"Regulatory feedback loop between TP73 and TRIM32.","date":"2013","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/23828567","citation_count":30,"is_preprint":false},{"pmid":"15175114","id":"PMC_15175114","title":"TP73 allelic expression in human brain and allele frequencies in Alzheimer's disease.","date":"2004","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15175114","citation_count":30,"is_preprint":false},{"pmid":"29482641","id":"PMC_29482641","title":"Transcription factors Tp73, Cebpd, Pax6, and Spi1 rather than DNA methylation regulate chronic transcriptomics changes after experimental traumatic brain injury.","date":"2018","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/29482641","citation_count":30,"is_preprint":false},{"pmid":"19111652","id":"PMC_19111652","title":"YAP and p73: a complex affair.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/19111652","citation_count":30,"is_preprint":false},{"pmid":"26247727","id":"PMC_26247727","title":"p53- and p73-independent activation of TIGAR expression in vivo.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/26247727","citation_count":29,"is_preprint":false},{"pmid":"11709051","id":"PMC_11709051","title":"Choosing between growth arrest and apoptosis through the retinoblastoma tumour suppressor protein, Abl and p73.","date":"2001","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/11709051","citation_count":29,"is_preprint":false},{"pmid":"31081944","id":"PMC_31081944","title":"The long noncoding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cells.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31081944","citation_count":29,"is_preprint":false},{"pmid":"17044134","id":"PMC_17044134","title":"Regulating p73 isoforms in human tumours.","date":"2006","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17044134","citation_count":29,"is_preprint":false},{"pmid":"23159862","id":"PMC_23159862","title":"Tissue-specific expression of p73 C-terminal isoforms in mice.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/23159862","citation_count":29,"is_preprint":false},{"pmid":"26266644","id":"PMC_26266644","title":"How Does p73 Cause Neuronal Defects?","date":"2015","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26266644","citation_count":28,"is_preprint":false},{"pmid":"17535448","id":"PMC_17535448","title":"Regulation of p73 by Hck through kinase-dependent and independent mechanisms.","date":"2007","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17535448","citation_count":28,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42234,"output_tokens":7978,"usd":0.123186,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17520,"output_tokens":5951,"usd":0.118188,"stage2_stop_reason":"end_turn"},"total_usd":0.241374,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"MDM2 binds p73 both in vivo and in vitro but, unlike with p53, does not promote p73 degradation. Instead, MDM2 suppresses p73 transcriptional activity by disrupting the p73-p300/CBP interaction, competing with p73 for binding to the p300/CBP N-terminus. p73 transcriptionally activates MDM2, forming a regulatory loop distinct from the p53-MDM2 loop.\",\n      \"method\": \"Co-immunoprecipitation (in vivo and in vitro), transient transfection/CAT reporter assays, apoptosis assays in p53-null cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP in vivo and in vitro, multiple orthogonal functional assays, replicated in multiple cell lines\",\n      \"pmids\": [\"10207051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MDM2 and MDMX bind p73α and p73β and, in contrast to their effect on p53, stabilize p73 protein (increase half-life) and enhance p73-mediated growth suppression and p21 induction.\",\n      \"method\": \"Co-immunoprecipitation, half-life assays, growth suppression assays\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding shown, half-life measured, single lab with two orthogonal methods\",\n      \"pmids\": [\"10469568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Tumor-derived p53 mutants (p53His175 and p53Gly281) physically associate with p73α, β, γ, and δ isoforms in vitro and in vivo. The core domain of mutant p53 is sufficient for the association; both the DNA-binding and oligomerization domains of p73 are required. This interaction functionally inhibits p73 transcriptional activity.\",\n      \"method\": \"Co-immunoprecipitation in breast cancer cell lines, in vitro binding, transactivation reporter assays, domain-mapping mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro and in vivo binding confirmed, domain mapping by mutagenesis, functional transcriptional assays, verified in endogenous tumor cell context\",\n      \"pmids\": [\"10884390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"E2F-1, c-Myc, and E1A oncogenes induce and activate endogenous p73α and p73β proteins in p53-deficient tumor cells, leading to p73-dependent transcription (p21, HDM2 induction) and apoptosis. A dominant-negative p73 inhibitor blocks oncogene-induced apoptosis.\",\n      \"method\": \"Western blot, reporter assays, apoptosis assays with dominant-negative p73 inhibitor in p53-null cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple oncogenes tested, functional reporter and apoptosis readouts, dominant-negative rescue, single lab\",\n      \"pmids\": [\"11115495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TCR-activation-induced cell death (TCR-AICD) requires both E2F-1 and p73 in a common pathway. E2F-1-null or p73-null primary T cells fail to undergo TCR-mediated apoptosis; dominant-negative E2F-1 or dominant-negative p73 protects T cells, whereas dominant-negative p53 does not.\",\n      \"method\": \"Genetic knockout (E2F-1-null, p73-null primary T cells), dominant-negative protein expression, apoptosis assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic null models plus dominant-negative rescue, p53-null control distinguishes pathway, replicated with two independent genetic systems\",\n      \"pmids\": [\"11034214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"p73 transcription is directly induced by p53 and by p73 itself (autoregulation) through a p53-binding site in the p73 promoter; mutant p53(R249S) and transcriptionally inactive p73β292 do not induce p73 expression.\",\n      \"method\": \"Reporter assays with p73 promoter constructs, site-directed mutagenesis of promoter binding site, RT-PCR\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter plus mutant controls, two orthogonal methods (reporter + endogenous mRNA), single lab\",\n      \"pmids\": [\"11314010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Combined loss of p63 and p73 (but not either alone) abolishes p53-dependent apoptosis in response to DNA damage in MEFs expressing E1A and in vivo, demonstrating that p63 and p73 are required co-factors for p53-mediated apoptosis.\",\n      \"method\": \"Mouse embryo fibroblasts deficient for combinations of p53 family members, E1A oncogene system, in vivo apoptosis assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic double/triple knockout mouse models, both in vitro and in vivo validation, rigorous epistasis analysis\",\n      \"pmids\": [\"11932750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"p73 is selectively expressed in Cajal-Retzius (CR) cells of the developing human cortex; in p73-/- mice, Reelin-expressing CR cells are absent at P2 (though early preplate Reelin from calretinin-positive cells remains), indicating p73 is required for CR cell identity/maintenance and cortical hem-derived neocortical development.\",\n      \"method\": \"Immunocytochemistry in human prenatal telencephalon, in situ hybridization in p73-/- mice, comparative analysis of p73-/- vs. wild-type cortex\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null mouse model with specific cellular phenotype, confirmed by two methods (IHC + ISH), single lab\",\n      \"pmids\": [\"12077194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"p73 is induced by a broad range of chemotherapeutic drugs; blocking p73 function with dominant-negative mutant, siRNA, or homologous recombination causes chemoresistance regardless of p53 status; mutant p53 can inactivate p73 and downregulation of mutant p53 enhances chemosensitivity.\",\n      \"method\": \"siRNA knockdown, dominant-negative expression, homologous recombination, chemosensitivity assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — three independent methods (DN, siRNA, HR) converge on same phenotype, multiple cell lines tested, direct p53-mutant/p73 functional connection established\",\n      \"pmids\": [\"12726865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Checkpoint kinases Chk1 and Chk2 control p73 induction at the mRNA level after DNA damage, acting through E2F1 stabilization. Interference with Chk1/Chk2 reduces p73 accumulation; augmentation increases it. E2F1 directs p73 expression both with and without DNA damage.\",\n      \"method\": \"Multiple experimental systems including kinase interference and augmentation, RT-PCR for p73 mRNA, E2F1 reporter assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple experimental systems, mRNA and protein level analysis, single lab with orthogonal approaches\",\n      \"pmids\": [\"15601819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Wwox physically interacts with p73 via its first WW domain; Src kinase phosphorylates Wwox at Tyr33 and enhances its binding to p73. Wwox expression redistributes nuclear p73 to the cytoplasm, suppressing p73 transcriptional activity; cytoplasmic p73 contributes to Wwox pro-apoptotic activity.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assays, subcellular fractionation, reporter assays, domain mapping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus subcellular localization plus functional reporter assays, domain mapping, single lab\",\n      \"pmids\": [\"15070730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Itch, a HECT ubiquitin-protein ligase, selectively binds and ubiquitinates p73 (but not p53), targeting p73 for rapid proteasome-dependent degradation. Upon DNA damage, Itch is downregulated, allowing p73 protein levels to rise.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, proteasome inhibitor experiments, Itch knockdown, Western blot for p73 stability\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct ubiquitination assay, Co-IP, proteasome inhibitor confirmation, knockdown rescue, specificity confirmed by lack of effect on p53\",\n      \"pmids\": [\"15678106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TAp73 induces apoptosis via: (i) direct transactivation of Scotin, causing ER stress; (ii) transactivation of PUMA (strong, lethal) and Bax promoters (weak, insufficient alone); and (iii) potential activation of the CD95 death receptor pathway. TAp73 also transactivates the DeltaNp73 promoter, creating a negative feedback.\",\n      \"method\": \"Promoter transactivation reporter assays, apoptosis assays in cell culture\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter assays for multiple targets, functional apoptosis readouts, single lab\",\n      \"pmids\": [\"15865927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"YAP1 (Yes-associated protein 1) interacts with p73 via the p73 PPPY motif and competes with Itch for the same binding site on p73, thereby preventing Itch-mediated ubiquitination and proteasomal degradation of p73. YAP1 knockdown reduces p73 accumulation and apoptosis after cisplatin treatment.\",\n      \"method\": \"Co-immunoprecipitation, competition binding assays, ubiquitination assays, siRNA knockdown, cisplatin treatment\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mechanistic competition between YAP1 and Itch for p73 PPPY motif demonstrated biochemically, ubiquitination assays, functional apoptosis rescue, siRNA validation\",\n      \"pmids\": [\"17110958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"p73 (or p53) directly transactivates endogenous p53 expression through binding to a defined p53-binding site in the p53 promoter; siRNA silencing of p73 reduces p53 transcription, and disruption of p53 autoregulation impairs cell cycle checkpoints and p53-mediated apoptosis.\",\n      \"method\": \"siRNA knockdown, reporter assays with p53 promoter mutants, RT-PCR for endogenous p53 mRNA, inducible interfering RNA\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter binding site mapped by mutagenesis, siRNA validation of endogenous effect, functional cell cycle phenotype, single lab\",\n      \"pmids\": [\"16849542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SIRT1 physically binds p73 and suppresses p73-dependent transcriptional activity; SIRT1 deacetylates p73 both in vivo and in vitro, partially inhibiting p73-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, deacetylation assays in vivo and in vitro, reporter assays, apoptosis assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro deacetylation assay plus in vivo confirmation, Co-IP, functional transcription and apoptosis readouts, single lab\",\n      \"pmids\": [\"16998810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Nutlin-3 disrupts endogenous TAp73α-HDM2 binding in p53-null cells, leading to increased p73 transcriptional activity (Noxa, PUMA, p21 upregulation), prolonged p73 half-life, and enhanced apoptosis; p73 siRNA rescues Nutlin-3-treated cells, confirming p73 dependence.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, RT-PCR for target genes, apoptosis assays, p73 half-life measurement\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous Co-IP, siRNA rescue, multiple target gene validation, half-life assay, single lab\",\n      \"pmids\": [\"17700533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Hck (Src-family kinase) interacts with p73 via its SH3 domain and phosphorylates p73 at Tyr28 (distinct from c-Abl which phosphorylates Tyr99). Hck co-expression stabilizes p73 in the cytoplasm (kinase-dependent) and represses p73 transcriptional activity and p73-mediated apoptosis through SH3-domain-dependent mechanisms.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding, site-directed mutagenesis of phosphorylation sites, subcellular fractionation, reporter assays, RT-PCR, apoptosis assays\",\n      \"journal\": \"BMC molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — site-directed mutagenesis identifies phosphorylation site, multiple functional readouts, both kinase-dependent and domain-dependent mechanisms, single lab\",\n      \"pmids\": [\"17535448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"p73 is cleaved by caspase-3 and caspase-8 during apoptosis induced by DNA-damaging drugs and TRAIL. TAp73 and caspase-cleavage products localize to mitochondria; recombinant p73 directly induces cytochrome c release from isolated mitochondria. A transcription-deficient TAp73 mutant enhances TRAIL-induced apoptosis, demonstrating transcription-independent pro-apoptotic function.\",\n      \"method\": \"In vitro caspase cleavage assays, subcellular fractionation, mitochondria isolation with cytochrome c release assay, siRNA knockdown, flow cytometry\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro reconstitution (cytochrome c release), fractionation, caspase cleavage assay, transcription-dead mutant, single lab\",\n      \"pmids\": [\"18362891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DNA damage-induced p73 activation and subsequent Noxa expression require NF-κB (p65); in p65-null MEFs, genotoxin treatment cannot induce p73 activity or Noxa mRNA expression, and cytochrome c release is compromised.\",\n      \"method\": \"p65-null MEFs, microarray gene profiling, RT-PCR, cytochrome c release assays\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null MEFs, microarray plus RT-PCR validation, functional apoptosis readout, single lab\",\n      \"pmids\": [\"20195489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"p73 selectively activates DNA damage repair in esophageal cells exposed to bile acids in acidic conditions via c-Abl kinase-dependent activation; p73 transcriptionally regulates base excision repair glycosylases SMUG1 and MUTYH. p73 deficiency in mice recapitulating bile acid exposure results in increased DNA damage.\",\n      \"method\": \"Human DNA repair PCR array, chromatin immunoprecipitation, reporter assays, c-Abl kinase inhibition, organotypic/traditional cell culture, surgical mouse model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct transcriptional regulation, in vivo mouse model confirms DNA damage phenotype, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"21891782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Crystal structures of the p73 DNA-binding domain (DBD) tetramer bound to response elements with different spacer lengths reveal that the compact tetramer interface is determined by half-site spacing; a 2-bp spacer unwinds DNA and reduces the tetramerization interface, while a 4-bp spacer prevents tetramerization. Functionally, p73 is more sensitive to spacer length than p53: a 1-bp spacer reduces p73 transactivation by 90%.\",\n      \"method\": \"X-ray crystallography, transactivation reporter assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures with multiple spacer lengths, directly correlated with functional transactivation data, multiple structures in one study\",\n      \"pmids\": [\"22474346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TAp73 activates serine biosynthesis in cancer cells not by directly regulating serine metabolic enzymes but by transcriptionally controlling glutaminase-2 (GLS2), a key glutaminolysis enzyme. p73-driven GLS2 expression converts glutamine to glutamate, which drives serine biosynthesis and GSH synthesis. TAp73 depletion abolishes cancer cell proliferation under serine/glycine deprivation.\",\n      \"method\": \"Metabolic profiling, siRNA knockdown, reporter assays, cell proliferation assays under nutrient deprivation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — metabolic profiling plus functional knockdown, indirect mechanism (via GLS2) established by reporter assays, single lab\",\n      \"pmids\": [\"24186203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TRIM32 (E3 ubiquitin ligase) is a direct transcriptional target of TAp73 in neural progenitor cells; TRIM32 in turn physically interacts with TAp73 and promotes its ubiquitination and degradation, establishing a negative feedback loop. ΔNp73 represses TRIM32 expression.\",\n      \"method\": \"ChIP, reporter assays, Co-immunoprecipitation, ubiquitination assays, Western blot\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct promoter binding, ubiquitination assay confirms degradation mechanism, Co-IP confirms physical interaction, single lab\",\n      \"pmids\": [\"23828567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"AMPK phosphorylates p73 on Ser426 in vitro and in vivo. AMPK activation prolongs p73 half-life, increases nuclear p73, and reduces Itch-mediated ubiquitination of p73. Chronic AMPK activation leads to p73-dependent apoptosis only in p53-expressing cells; p73 is required for p53 stabilization under AMPK activation but not under DNA damage.\",\n      \"method\": \"In vitro kinase assay, in vivo phosphorylation assay, half-life measurement, ubiquitination assays, p73 knockdown, co-immunoprecipitation\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay identifies phosphorylation site, in vivo confirmation, functional consequences measured by multiple methods, single rigorous study\",\n      \"pmids\": [\"24874608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MDM2 differentially regulates mutant p53 interactions with p63 and p73: MDM2 inhibits p63 binding to p53R175H (conformational mutant) but enhances the weaker p53R273H/p73 interaction. MDM2 can relieve p63 inhibition by p53R175H but forms a trimeric complex with p73 and p53R273H/R175H to enhance p73 inhibition.\",\n      \"method\": \"Co-immunoprecipitation, reporter assays, domain mapping\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional reporter assays, differential effects mapped across mutants, single lab\",\n      \"pmids\": [\"25417702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NAMPT inhibition stabilizes p73 independently of p53 through increased acetylation and decreased ubiquitination, leading to enhanced autophagy and cancer cell death; these effects are reversed by NMN (the NAMPT enzymatic product), establishing a NAMPT-p73 nexus in cancer cell viability.\",\n      \"method\": \"NAMPT pharmacological inhibition and siRNA knockdown, p73 overexpression/knockdown, ubiquitination assays, Western blot, cell viability assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic inhibition converge, rescue with enzymatic product, ubiquitination assays, single lab\",\n      \"pmids\": [\"26586573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"p73 is required for ependymal cell maturation and planar cell polarity establishment in the developing SVZ; p73-deficient ependymal cells have impaired ciliogenesis and fail to organize into pinwheels, disrupting SVZ niche architecture and neurogenesis.\",\n      \"method\": \"Genetic knockout mouse model (p73-null), immunofluorescence, electron microscopy, neurogenesis assays\",\n      \"journal\": \"Developmental neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null model with defined cellular phenotype (ciliogenesis, pinwheel organization), multiple morphological methods, single lab\",\n      \"pmids\": [\"26482843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"p73 is expressed in multiciliated cells (MCCs) and is required for MCC differentiation; p73 directly regulates Foxj1 (a master transcriptional regulator of multiciliogenesis) and >100 cilia-associated target genes. Loss of p73 causes defects in ciliogenesis explaining hydrocephalus, hippocampal dysgenesis, sterility, and chronic inflammation in p73-null mice.\",\n      \"method\": \"ChIP-seq (p73 and p63) in murine tracheal cells, genetic knockout mice, reporter assays, immunofluorescence\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP-seq identifies direct target genes, genetic null model confirms phenotype, validated across multiple target genes with orthogonal methods\",\n      \"pmids\": [\"26947080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TAp73 directly activates POSTN (periostin) transcription in glioblastoma cells, conferring an invasive phenotype. POSTN overexpression rescues the reduced invasiveness caused by p73 knockdown, placing POSTN downstream of TAp73 in a pro-invasion pathway.\",\n      \"method\": \"ChIP, reporter assays, siRNA knockdown, invasion assays, rescue experiments with POSTN overexpression\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct promoter binding, siRNA knockdown with functional readout, rescue experiment validates pathway, single lab\",\n      \"pmids\": [\"26930720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Δ133p53 forms a complex with p73 upon γ-irradiation; co-expression of Δ133p53 and p73 synergistically promotes DNA DSB repair (HR, NHEJ, SSA) by jointly binding to both a Δ133p53-responsive element and a p73-RE in the promoters of RAD51, LIG4, and RAD52. Loss of p73 increases DNA damage accumulation and leads to cell cycle arrest and senescence.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, reporter assays, γ-irradiation, HR/NHEJ/SSA repair assays, siRNA knockdown\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and co-IP confirm complex formation at target promoters, multiple repair pathway assays, functional phenotype with siRNA, single lab\",\n      \"pmids\": [\"29511339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"JNK-mediated phosphorylation of Thr81 in the proline-rich domain of p53 enables wild-type p53 (as well as mutant p53) to form a complex with p73. Wild-type p53/p73 dimerization facilitates expression of apoptotic target genes (PUMA, BAX) and promotes apoptosis; mutant p53/p73 complex suppresses apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assays, structural modeling, reporter assays, apoptosis assays, site-directed mutagenesis of Thr81\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with phosphomimetic and phospho-dead mutants, functional apoptosis readouts, structural prediction, single lab\",\n      \"pmids\": [\"29615516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TAp73 is an essential regulator of ependymal planar cell polarity (PCP) by modulating actin and microtubule cytoskeleton dynamics. TAp73 regulates translational PCP and actin dynamics through modulation of non-muscle myosin-II activity and controls asymmetric localization of PCP-core signaling modules and polarized microtubule dynamics for rotational PCP.\",\n      \"method\": \"TAp73-specific knockout mice, immunofluorescence for PCP proteins and cytoskeletal markers, analysis of myosin-II activity\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific genetic null model, multiple cytoskeletal readouts, mechanistic link to non-muscle myosin-II, single lab\",\n      \"pmids\": [\"30518789\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TP73 encodes a p53-family transcription factor that is activated by DNA damage (via the Chk1/Chk2–E2F1 axis and c-Abl-dependent mechanisms), stabilized by YAP1 and AMPK-mediated phosphorylation (Ser426) competing with Itch-mediated ubiquitination and degradation, and that directly transactivates pro-apoptotic targets (PUMA, Bax, CD95, Noxa) and DNA repair genes (SMUG1, MUTYH, RAD51, LIG4); it is also a master transcriptional regulator of multiciliogenesis (via Foxj1 and cilia-associated genes), ependymal planar cell polarity (via non-muscle myosin-II and cytoskeletal dynamics), and Cajal-Retzius cell identity in the developing cortex, while its activity is inhibited by dominant-negative ΔNp73 isoforms, mutant p53 (gain-of-function binding to p73's DNA-binding domain), MDM2 (which blocks p73–p300/CBP interaction), SIRT1 (deacetylation), and WWOX (cytoplasmic sequestration).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TP73 encodes a p53-family transcription factor that operates as a stress-activated transcriptional hub coupling genotoxic and oncogenic signals to apoptosis, DNA repair, and developmental cell-fate programs [#4, #8, #28]. Following DNA damage, p73 is induced at the mRNA level through a Chk1/Chk2-E2F1 axis [#9], and p73-dependent apoptosis is a shared output with E2F1 (as in TCR-activation-induced T-cell death) that operates independently of p53 [#4]; p63 and p73 together are required co-factors for p53-mediated apoptosis after DNA damage [#6]. Once stabilized, TAp73 directly transactivates pro-apoptotic targets including PUMA, Bax, Scotin, and Noxa — the latter requiring NF-κB (p65) [#12, #19] — and also acts transcription-independently at mitochondria, where caspase-cleaved p73 drives cytochrome c release [#18]. p73 additionally directs DNA repair, transcribing the base-excision-repair glycosylases SMUG1 and MUTYH via c-Abl-dependent activation [#20] and, in complex with Δ133p53, the double-strand-break repair genes RAD51, LIG4, and RAD52 [#30]. p73 abundance is set by a balance of ubiquitin-dependent turnover and stabilizing modifications: the HECT ligase Itch selectively ubiquitinates p73 for proteasomal degradation and is downregulated upon DNA damage [#11], while YAP1 competes with Itch for the p73 PPPY motif to protect it [#13] and AMPK phosphorylation at Ser426 prolongs its half-life by reducing Itch-mediated ubiquitination [#24]. Its transcriptional activity is further restrained by MDM2, which disrupts the p73-p300/CBP interaction [#0], by tumor-derived mutant p53 that binds the p73 DNA-binding/oligomerization domains [#2], by SIRT1-mediated deacetylation [#15], and by WWOX-driven cytoplasmic sequestration [#10]. Beyond tumor suppression, p73 is a master regulator of multiciliogenesis, directly controlling Foxj1 and >100 cilia genes [#28], and is required for ependymal planar cell polarity through non-muscle myosin-II and cytoskeletal dynamics [#32] and for Cajal-Retzius cell identity in the developing cortex [#7]. Crystallographic analysis shows the p73 DNA-binding domain tetramerizes on response elements in a manner acutely sensitive to half-site spacing [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that p73, despite binding MDM2, is regulated differently from p53 — MDM2 inhibits p73 transcription by displacing p300/CBP rather than degrading it, defining a distinct regulatory loop.\",\n      \"evidence\": \"Reciprocal Co-IP in vivo/in vitro plus CAT reporter and apoptosis assays in p53-null cells\",\n      \"pmids\": [\"10207051\", \"10469568\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conflicting reports on whether MDM2/MDMX stabilize versus suppress p73 activity\", \"Physiological conditions favoring each outcome not defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Connected p73 to oncogene- and damage-driven apoptosis independent of p53, showing E2F1/c-Myc/E1A activate endogenous p73 and that p73 is required for TCR-induced T-cell death.\",\n      \"evidence\": \"Dominant-negative inhibition, genetic E2F1-null and p73-null primary T cells, apoptosis assays\",\n      \"pmids\": [\"11115495\", \"11034214\", \"10884390\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets driving apoptosis not yet enumerated\", \"Mechanism by which mutant p53 inhibits p73 mapped only to domains, not at structural resolution\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed p63 and p73 are jointly required for p53-dependent apoptosis and that p73 marks Cajal-Retzius cells, establishing both a tumor-suppressor cofactor role and a developmental function.\",\n      \"evidence\": \"Combinatorial p53-family knockout MEFs/in vivo; immunocytochemistry and ISH in p73-/- cortex\",\n      \"pmids\": [\"11932750\", \"12077194\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of p63/p73 cooperativity with p53 not resolved\", \"Cajal-Retzius transcriptional targets of p73 unidentified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined p73 as a determinant of chemosensitivity across p53 backgrounds, with mutant p53 acting as an inhibitor that can be relieved to restore drug response.\",\n      \"evidence\": \"Convergent siRNA, dominant-negative, and homologous-recombination loss-of-function chemosensitivity assays\",\n      \"pmids\": [\"12726865\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which p73 target genes mediate chemosensitivity not specified\", \"Generalizability across tumor types not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified the upstream signaling that induces p73 after DNA damage, placing Chk1/Chk2 and E2F1 stabilization upstream of p73 mRNA accumulation.\",\n      \"evidence\": \"Kinase interference/augmentation, RT-PCR, E2F1 reporter assays\",\n      \"pmids\": [\"15601819\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct E2F1 occupancy of the p73 promoter not shown here\", \"Relative contribution of Chk1 versus Chk2 unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Revealed cytoplasmic sequestration as a control point: WWOX binds p73 and relocalizes it to the cytoplasm, with Src-mediated phosphorylation tuning the interaction.\",\n      \"evidence\": \"Co-IP, in vitro binding, subcellular fractionation, domain mapping, reporter assays\",\n      \"pmids\": [\"15070730\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding without reciprocal validation in other systems\", \"Physiological signals controlling WWOX-p73 partitioning unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined the dominant proteostatic control of p73 — Itch-mediated, p53-sparing ubiquitination and degradation that is relieved by DNA damage.\",\n      \"evidence\": \"Ubiquitination assays, Co-IP, proteasome inhibition, Itch knockdown\",\n      \"pmids\": [\"15678106\", \"15865927\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal that downregulates Itch after damage not defined\", \"Isoform selectivity of Itch toward TA versus ΔNp73 not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapped the molecular logic of p73 stabilization: YAP1 competes with Itch at the p73 PPPY motif to protect it from degradation, gating cisplatin-induced apoptosis.\",\n      \"evidence\": \"Competition binding and ubiquitination assays, siRNA, cisplatin treatment\",\n      \"pmids\": [\"17110958\", \"16849542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream regulators of YAP1-p73 binding under damage not defined\", \"How p73-driven p53 autoregulation integrates with this axis unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Expanded the inhibitory and pharmacological control of p73 — SIRT1 deacetylation and Hck-mediated cytoplasmic retention repress activity, while Nutlin-3 frees p73 from HDM2 to drive apoptosis in p53-null cells.\",\n      \"evidence\": \"Co-IP, in vitro/in vivo deacetylation, site-directed mutagenesis, endogenous Co-IP, siRNA rescue, target-gene RT-PCR\",\n      \"pmids\": [\"16998810\", \"17535448\", \"17700533\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each mechanism shown by a single lab without cross-validation\", \"In vivo relevance of Hck and SIRT1 control of p73 not established\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated a transcription-independent, mitochondrial arm of p73 apoptosis, with caspase cleavage products directly triggering cytochrome c release.\",\n      \"evidence\": \"In vitro caspase cleavage, mitochondrial fractionation and cytochrome c release, transcription-dead mutant, flow cytometry\",\n      \"pmids\": [\"18362891\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of p73 action at mitochondria unknown\", \"Relative contribution of transcriptional versus mitochondrial arms in vivo unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Placed NF-κB (p65) as a required cofactor for damage-induced p73 activity and Noxa induction, linking inflammatory signaling to p73-driven apoptosis.\",\n      \"evidence\": \"p65-null MEFs, microarray and RT-PCR, cytochrome c release\",\n      \"pmids\": [\"20195489\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical p65-p73 interaction not demonstrated here\", \"Mechanism of p65 requirement (cofactor vs upstream) unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established p73 as a direct transcriptional activator of DNA repair, controlling base-excision-repair glycosylases SMUG1 and MUTYH via c-Abl in genotoxin-exposed epithelium.\",\n      \"evidence\": \"ChIP, DNA-repair PCR array, reporter assays, c-Abl inhibition, surgical mouse model\",\n      \"pmids\": [\"21891782\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Breadth of p73-regulated repair genes beyond BER not defined here\", \"Single-lab finding in a specialized esophageal context\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Provided the structural basis for p73 DNA recognition, showing tetramerization on response elements is acutely sensitive to half-site spacing — more so than p53.\",\n      \"evidence\": \"X-ray crystallography of DBD tetramers with varied spacers, transactivation assays\",\n      \"pmids\": [\"22474346\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length p73 structure and isoform differences not captured\", \"How cofactors alter response-element selectivity unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended p73's reach to metabolism and developmental feedback — driving serine biosynthesis via GLS2 and forming a TRIM32 negative-feedback loop in neural progenitors.\",\n      \"evidence\": \"Metabolic profiling, siRNA, ChIP, Co-IP, ubiquitination assays, proliferation under nutrient deprivation\",\n      \"pmids\": [\"24186203\", \"23828567\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect metabolic targets only partially separated\", \"Physiological context of TRIM32 feedback beyond neural progenitors unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified AMPK Ser426 phosphorylation as a stabilizing signal that opposes Itch and integrates energy stress with p73-dependent apoptosis, and detailed MDM2's differential modulation of mutant-p53/p73 complexes.\",\n      \"evidence\": \"In vitro/in vivo kinase and ubiquitination assays, half-life measurement, p73 knockdown; Co-IP and reporter assays across p53 mutants\",\n      \"pmids\": [\"24874608\", \"25417702\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How AMPK and DNA-damage inputs are prioritized at p73 unclear\", \"Trimeric MDM2/mutant-p53/p73 complex stoichiometry not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Refined p73 proteostatic control through metabolism, showing NAMPT inhibition stabilizes p73 via increased acetylation and decreased ubiquitination to drive autophagy and death; ependymal maturation and PCP also depend on p73.\",\n      \"evidence\": \"NAMPT pharmacological/genetic inhibition with NMN rescue, ubiquitination assays; p73-null mouse SVZ imaging and EM\",\n      \"pmids\": [\"26586573\", \"26482843\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzyme(s) mediating NAMPT-dependent p73 acetylation not identified\", \"Direct p73 targets driving ependymal ciliogenesis not enumerated here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined p73 as the master transcriptional driver of multiciliogenesis through direct control of Foxj1 and cilia genes, and as a pro-invasion factor via POSTN in glioblastoma.\",\n      \"evidence\": \"ChIP-seq in tracheal cells, knockout mice, reporter assays; ChIP, siRNA, invasion and rescue assays\",\n      \"pmids\": [\"26947080\", \"26930720\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isoform (TA vs ΔN) responsible for cilia program not fully dissected\", \"Cofactors directing p73 to cilia versus apoptotic promoters unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established cooperative complexes that diversify p73 output — Δ133p53/p73 promoting DSB repair gene expression, and JNK-driven p53-Thr81 phosphorylation enabling wild-type or mutant p53/p73 dimers with opposite apoptotic outcomes; TAp73 controls ependymal PCP via myosin-II and cytoskeletal dynamics.\",\n      \"evidence\": \"Co-IP, ChIP, HR/NHEJ/SSA repair assays; phosphomutant Co-IP and apoptosis assays; isoform-specific knockout mice with cytoskeletal imaging\",\n      \"pmids\": [\"29511339\", \"29615516\", \"30518789\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of p53-isoform/p73 heterocomplexes not resolved\", \"How the same complexes switch between repair and apoptosis outputs unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many competing inputs (Itch/YAP1/AMPK turnover, SIRT1/MDM2/WWOX inhibition, p53-isoform complexes) are integrated to select between p73's apoptotic, DNA-repair, metabolic, and ciliogenic programs in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking post-translational state to target-gene program choice\", \"Isoform-resolved (TAp73 vs ΔNp73) genome-wide occupancy across contexts incomplete\", \"In vivo hierarchy of stabilizing versus degrading inputs undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [12, 20, 28, 29, 30]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [21, 30]},\n      {\"term_id\": \"GO:0140297\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [10, 24]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10, 17]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 12, 18]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [12, 28]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [20, 30]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 27, 28, 32]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [26]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MDM2\", \"TP53\", \"YAP1\", \"ITCH\", \"WWOX\", \"SIRT1\", \"TRIM32\", \"TP63\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}